Pathogen transmission in relation to duration of attachment by Ixodes scapularis ticks
Publication date: Available online 31 January 2018 Source:Ticks and Tick-borne Diseases Author(s): Lars Eisen The blacklegged tick, Ixodes scapularis, is the primary vector to humans in the eastern United States of the deer tick virus lineage of Powassan virus (Powassan virus disease); the protozoan parasite Babesia microti (babesiosis); and multiple bacterial disease agents including Anaplasma phagocytophilum (anaplasmosis), Borrelia burgdorferi and Borrelia mayonii (Lyme disease), Borrelia miyamotoi (relapsing fever-like illness, named Borrelia miyamotoi disease), and Ehrlichia muris eauclairensis (a minor causative agent of ehrlichiosis). With the notable exception of Powassan virus, which can be transmitted within minutes after attachment by an infected tick, there is no doubt that the risk of transmission of other I. scapularis-borne pathogens, including Lyme disease spirochetes, increases with the length of time (number of days) infected ticks are allowed to remain attached. This review summarizes data from experimental transmission studies to reinforce the important disease-prevention message that regular (at least daily) tick checks and prompt tick removal has strong potential to reduce the risk of transmission of I. scapularis-borne bacterial and parasitic pathogens from infected attached ticks. The most likely scenario for human exposure to an I. scapularis-borne pathogen is the bite by a single infected tick. However, recent reviews have failed to make a clear dis...
Timely medication access in pediatric oncology is important; yet barriers are poorly described. We surveyed pediatric oncology health care providers at National Cancer Institute Community Oncology Research Program sites on their experience with the impact of drug acquisition difficulties, prior authorization (PA) requests, insurance denials, and patient copays leading to deviations or delays from prescribed treatment for their pediatric/adolescent/young adult patients in calendar year 2016. PA requests, the most frequently cited issue, created a deviation or delay from planned chemotherapy and supportive care treatment in ...
President Donald Trump is pledging to continue battling the deadly epidemic of opioid drug abuse "until our job is done."
U.S. President Donald Trump touted progress in the fight against opioid abuse on Wednesday and promised to hold drugmakers accountable for their part in the crisis, a day after his administration brought its first related criminal charges against a major drug distributor and company executives.
At least 673 cases have been reported in 22 states for 2019, according to a tally by The Washington Post of available state and local health department data.
Conclusions/Importance: These findings imply the need for screening and prevention education about substance use in child welfare populations, particularly in regards to inhalant use. PMID: 31008676 [PubMed - as supplied by publisher]
CONCLUSIONS: HTO are prevalent among college populations but their prevalence and etiology are not well understood. This likely leads to systematic undercounting of the impact of alcohol in college settings, exacerbating the "translation" gap between what the research says is effective and what colleges actually do. Better understanding of HTO mechanisms through which drinkers harm those around them would inform alcohol research and policy on college campuses, and lead to more accurate assessments of the degree to which stronger alcohol policies could benefit all students, regardless of their drinking patterns. ...
President Donald Trump says his administration is using every resource it has to fight the nation's opioid crisis
Measles cases in the United States have surpassed the highest number on record since the disease was declared eliminated nationwide in 2000.
CONCLUSIONS: A digital point-of-care solution that generates customized product handouts with clinical, coverage, pricing, and supplier information may significantly improve patient adherence while saving clinicians time. PMID: 31008719 [PubMed - in process]
This is the first repositionable and fully retrievable transcatheter aortic valve replacement device available in the United States.FDA Approvals